P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)

Detalles Bibliográficos
Autores principales: Hernandez-Ilizaliturri, F. J., Kuruvilla, J., Christian, B. A., Flinn, I. W., Assouline, S. E., Ulrickson, M. L., Landsburg, D. J., Stuart, M., Lowman, H., Levin, N., Maetzel, D., Viller, N. N., MacLaren, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430507/
http://dx.doi.org/10.1097/01.HS9.0000847476.69621.cd
_version_ 1784779788275154944
author Hernandez-Ilizaliturri, F. J.
Kuruvilla, J.
Christian, B. A.
Flinn, I. W.
Assouline, S. E.
Ulrickson, M. L.
Landsburg, D. J.
Stuart, M.
Lowman, H.
Levin, N.
Maetzel, D.
Viller, N. N.
MacLaren, A.
author_facet Hernandez-Ilizaliturri, F. J.
Kuruvilla, J.
Christian, B. A.
Flinn, I. W.
Assouline, S. E.
Ulrickson, M. L.
Landsburg, D. J.
Stuart, M.
Lowman, H.
Levin, N.
Maetzel, D.
Viller, N. N.
MacLaren, A.
author_sort Hernandez-Ilizaliturri, F. J.
collection PubMed
description
format Online
Article
Text
id pubmed-9430507
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94305072022-08-31 P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL) Hernandez-Ilizaliturri, F. J. Kuruvilla, J. Christian, B. A. Flinn, I. W. Assouline, S. E. Ulrickson, M. L. Landsburg, D. J. Stuart, M. Lowman, H. Levin, N. Maetzel, D. Viller, N. N. MacLaren, A. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430507/ http://dx.doi.org/10.1097/01.HS9.0000847476.69621.cd Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Hernandez-Ilizaliturri, F. J.
Kuruvilla, J.
Christian, B. A.
Flinn, I. W.
Assouline, S. E.
Ulrickson, M. L.
Landsburg, D. J.
Stuart, M.
Lowman, H.
Levin, N.
Maetzel, D.
Viller, N. N.
MacLaren, A.
P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)
title P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)
title_full P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)
title_fullStr P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)
title_full_unstemmed P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)
title_short P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)
title_sort p1152: results from a phase i pharmacokinetic (pk) and safety study of trph-222, a novel cd22-targeting antibody-drug conjugate, in patients with relapsed/refractory b-cell non-hodgkin lymphoma (r/r nhl)
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430507/
http://dx.doi.org/10.1097/01.HS9.0000847476.69621.cd
work_keys_str_mv AT hernandezilizaliturrifj p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl
AT kuruvillaj p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl
AT christianba p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl
AT flinniw p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl
AT assoulinese p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl
AT ulricksonml p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl
AT landsburgdj p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl
AT stuartm p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl
AT lowmanh p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl
AT levinn p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl
AT maetzeld p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl
AT villernn p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl
AT maclarena p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl

Ejemplares similares